Limits...
Effectiveness of the First Dose of BCG against Tuberculosis among HIV-Infected, Predominantly Immunodeficient Children.

Van-Dunem JC, Rodrigues LC, Alencar LC, Militão-Albuquerque Mde F, Ximenes RA - Biomed Res Int (2015)

Bottom Line: The crude effectiveness was 8% (95% CI: -26 to 32) and the adjusted effectiveness was 30% (95% CI: -75 to 72).The present study suggests that BCG does not have a protective effect against tuberculosis among immunodeficient HIV-infected children.Accepting that these findings should be considered with caution, they are nonetheless likely to be the last estimate of BCG efficacy in a sufficiently powered study.

View Article: PubMed Central - PubMed

Affiliation: Departamento de Pediatria, Universidade Agostinho Neto, Avenida Amilcar Cabral, s/n, Maianga, Luanda, Angola.

ABSTRACT
The objective of this study was to estimate the protective effect of Bacille Calmette-Guérin (BCG) vaccine against tuberculosis among (predominantly immunodeficient) HIV-infected children in Angola. A hospital-based case-control study was conducted with 230 cases, children coinfected with tuberculosis, and 672 controls, HIV-infected children from the same hospital, aged 18 months to 13 years. The presence of a vaccination scar was taken as a proxy marker for BCG vaccination. The crude effectiveness was 8% (95% CI: -26 to 32) and the adjusted effectiveness was 30% (95% CI: -75 to 72). The present study suggests that BCG does not have a protective effect against tuberculosis among immunodeficient HIV-infected children. Since BCG is no longer given to HIV-infected children, the study may not be replicated. Accepting that these findings should be considered with caution, they are nonetheless likely to be the last estimate of BCG efficacy in a sufficiently powered study.

No MeSH data available.


Related in: MedlinePlus

Selection of the study population. ∗Staff responsible for the X-ray reading discovered the diagnostic hypothesis before delivering the report.
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4499653&req=5

fig1: Selection of the study population. ∗Staff responsible for the X-ray reading discovered the diagnostic hypothesis before delivering the report.

Mentions: A total of 231 cases were recruited. Of these, one was excluded because staff responsible for X-ray reading discovered the diagnostic hypothesis before delivering the report, which could have led to misclassification. A total of 230 cases and 672 controls were selected. Exclusion criteria and number of patients excluded are presented in Figure 1. Of the 230 cases, 156 (67.8%) were recruited from inpatients, while this percentage was 33% among the controls.


Effectiveness of the First Dose of BCG against Tuberculosis among HIV-Infected, Predominantly Immunodeficient Children.

Van-Dunem JC, Rodrigues LC, Alencar LC, Militão-Albuquerque Mde F, Ximenes RA - Biomed Res Int (2015)

Selection of the study population. ∗Staff responsible for the X-ray reading discovered the diagnostic hypothesis before delivering the report.
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4499653&req=5

fig1: Selection of the study population. ∗Staff responsible for the X-ray reading discovered the diagnostic hypothesis before delivering the report.
Mentions: A total of 231 cases were recruited. Of these, one was excluded because staff responsible for X-ray reading discovered the diagnostic hypothesis before delivering the report, which could have led to misclassification. A total of 230 cases and 672 controls were selected. Exclusion criteria and number of patients excluded are presented in Figure 1. Of the 230 cases, 156 (67.8%) were recruited from inpatients, while this percentage was 33% among the controls.

Bottom Line: The crude effectiveness was 8% (95% CI: -26 to 32) and the adjusted effectiveness was 30% (95% CI: -75 to 72).The present study suggests that BCG does not have a protective effect against tuberculosis among immunodeficient HIV-infected children.Accepting that these findings should be considered with caution, they are nonetheless likely to be the last estimate of BCG efficacy in a sufficiently powered study.

View Article: PubMed Central - PubMed

Affiliation: Departamento de Pediatria, Universidade Agostinho Neto, Avenida Amilcar Cabral, s/n, Maianga, Luanda, Angola.

ABSTRACT
The objective of this study was to estimate the protective effect of Bacille Calmette-Guérin (BCG) vaccine against tuberculosis among (predominantly immunodeficient) HIV-infected children in Angola. A hospital-based case-control study was conducted with 230 cases, children coinfected with tuberculosis, and 672 controls, HIV-infected children from the same hospital, aged 18 months to 13 years. The presence of a vaccination scar was taken as a proxy marker for BCG vaccination. The crude effectiveness was 8% (95% CI: -26 to 32) and the adjusted effectiveness was 30% (95% CI: -75 to 72). The present study suggests that BCG does not have a protective effect against tuberculosis among immunodeficient HIV-infected children. Since BCG is no longer given to HIV-infected children, the study may not be replicated. Accepting that these findings should be considered with caution, they are nonetheless likely to be the last estimate of BCG efficacy in a sufficiently powered study.

No MeSH data available.


Related in: MedlinePlus